Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer

[1]  C. Clendenin,et al.  Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages. , 2015, Gastroenterology.

[2]  S. Pothula,et al.  Pancreatic cancer: The microenvironment needs attention too! , 2015, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[3]  D. Tuveson,et al.  Stromal biology and therapy in pancreatic cancer: a changing paradigm , 2015, Gut.

[4]  G. Sarosi,et al.  Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements. , 2015, The American journal of pathology.

[5]  P. Kris-Etherton,et al.  In vitro Production of IL-6 and IFN-γ is Influenced by Dietary Variables and Predicts Upper Respiratory Tract Infection Incidence and Severity Respectively in Young Adults , 2015, Front. Immunol..

[6]  E. Furth,et al.  Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma , 2015, Cancer Immunology Research.

[7]  R. Jesenofsky,et al.  Desmoplasia and Chemoresistance in Pancreatic Cancer , 2014, Cancers.

[8]  Gisele Monteiro,et al.  Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. , 2014, European journal of pharmacology.

[9]  N. Jamieson,et al.  IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival , 2014, Oncotarget.

[10]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[11]  T. Giese,et al.  Prevailing Role of Contact Guidance in Intrastromal T-cell Trapping in Human Pancreatic Cancer , 2014, Clinical Cancer Research.

[12]  Derek S. Chan,et al.  Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.

[13]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[14]  S. Sebti,et al.  Selective Disruption of Rb–Raf-1 Kinase Interaction Inhibits Pancreatic Adenocarcinoma Growth Irrespective of Gemcitabine Sensitivity , 2013, Molecular Cancer Therapeutics.

[15]  L. Diaz,et al.  Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer , 2013, Journal of immunotherapy.

[16]  A. Levchenko,et al.  Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis. , 2012, The Journal of clinical investigation.

[17]  S. Chellappan,et al.  Nicotine induces inhibitor of differentiation-1 in a Src-dependent pathway promoting metastasis and chemoresistance in pancreatic adenocarcinoma. , 2012, Neoplasia.

[18]  M. Choudhry,et al.  Activation of Toll-Like Receptor 2 Prevents Suppression of T-Cell Interferon γ Production by Modulating p38/Extracellular Signal-Regulated Kinase Pathways following Alcohol and Burn Injury , 2012, Molecular medicine.

[19]  Alexander A. Fingerle,et al.  The role of stroma in pancreatic cancer: diagnostic and therapeutic implications , 2012, Nature Reviews Gastroenterology &Hepatology.

[20]  N. Jhala,et al.  Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. , 2012, Cancer cell.

[21]  O. Wolkenhauer,et al.  Studies on mechanisms of interferon-gamma action in pancreatic cancer using a data-driven and model-based approach , 2011, Molecular Cancer.

[22]  James O. Jones,et al.  Suppression of Antitumor Immunity by Stromal Cells Expressing , 2022 .

[23]  L. Sherman,et al.  CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. , 2010, Cancer research.

[24]  S. Rosenberg,et al.  Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma , 2010, Journal of immunotherapy.

[25]  Huamin Wang,et al.  Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. , 2009, Cancer research.

[26]  Matthias Schäfer,et al.  Cancer as an overhealing wound: an old hypothesis revisited , 2008, Nature Reviews Molecular Cell Biology.

[27]  G. Gallick,et al.  Development and Characterization of Gemcitabine-Resistant Pancreatic Tumor Cells , 2007, Annals of Surgical Oncology.

[28]  D. Tuveson,et al.  Dynamics of the immune reaction to pancreatic cancer from inception to invasion. , 2007, Cancer research.

[29]  Helmut Friess,et al.  Pancreatic cancer microenvironment , 2007, International journal of cancer.

[30]  B. Shalmon,et al.  CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. , 2007, Cancer research.

[31]  Michael G. Johnson,et al.  Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. , 2006, Cancer research.

[32]  G. Willimsky,et al.  Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance , 2005, Nature.

[33]  J. Trevino,et al.  Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. , 2005, Cancer research.

[34]  E. Jaffee,et al.  Immunotherapy for pancreatic cancer — science driving clinical progress , 2005, Nature Reviews Cancer.

[35]  R. Hruban,et al.  Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients , 2004, The Journal of experimental medicine.

[36]  T. Manabe,et al.  Pivotal Role of CXCR3 in Melanoma Cell Metastasis to Lymph Nodes , 2004, Cancer Research.

[37]  Tasuku Honjo,et al.  PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells , 2004, Cancer Research.

[38]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[39]  Verhoef,et al.  Lymphocyte Stimulation by CD3‐CD28 Enables Detection of Low T Cell Interferon‐γ and Interleukin‐4 Production in Rheumatoid Arthritis , 1999, Scandinavian journal of immunology.

[40]  I. Fidler,et al.  In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. , 1999, Neoplasia.

[41]  R. Schmid,et al.  Identification, culture, and characterization of pancreatic stellate cells in rats and humans. , 1998, Gastroenterology.

[42]  R. Schreiber,et al.  Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .

[43]  S. Ramakrishna,et al.  Immune system: a double-edged sword in cancer , 2013, Inflammation Research.

[44]  M. Serio,et al.  Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. , 2001, The Journal of clinical investigation.

[45]  R. Schreiber,et al.  Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[46]  U. Boehm,et al.  Cellular responses to interferon-gamma. , 1997, Annual review of immunology.